Loading...
AMYT logo

Amryt Pharma plcNasdaqGS:AMYT Aktienübersicht

Marktkapitalisierung US$940.7m
Aktienkurs
n/a
US$20.75
k. A.intrinsischer Abschlag
1Y86.5%
7D0.7%
1D
Wert des Portfolios
​
Siehe

Amryt Pharma plc

NasdaqGS:AMYT Lagerbericht

Marktkapitalisierung: US$940.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Amryt Pharma (AMYT) Aktienübersicht

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. Mehr Details

AMYT grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung2/6
Künftiges Wachstum5/6
Vergangene Leistung0/6
Finanzielle Gesundheit4/6
Dividenden0/6

Belohnungen

Prognostiziertes Gewinnwachstum 53.88% pro Jahr

Die Erträge sind in den letzten 5 Jahren um 34.4% pro Jahr gestiegen.

Risikoanalyse

Bei unseren Risikoprüfungen wurden keine Risiken für AMYT festgestellt.

AMYT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Amryt Pharma plc Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Amryt Pharma
Historische Aktienkurse
Aktueller AktienkursUS$14.70
52-Wochen-HochUS$14.77
52-Wochen-TiefUS$6.41
Beta0.75
1 Monat Veränderung0.96%
3 Monate Veränderung-0.14%
1 Jahr Veränderung86.55%
3 Jahre Veränderungn/a
5 Jahre Veränderungn/a
Veränderung seit IPO84.91%

Aktuelle Nachrichten und Updates

Seeking Alpha • Oct 18

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

A committee of the European Medicines Agency (EMA) recommended that the orphan disease designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat acromegaly in the EU is maintained. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The EMA's Committee for Orphan Medicinal Products (COMP) adopted the positive opinion. "The COMP recommendation to maintain the orphan disease designation for Mycapssa confirms the significant benefit of Mycapssa over the currently available injectable forms of somatostatin analogues, which represents a significant development for acromegaly sufferers in Europe," said Amryt CEO Joe Wiley. In September, EMA's Committee for Medicinal Products for Human Use (CHMP) had recommended the approval of Mycapssa as a maintenance therapy for certain patients with acromegaly. The orphan drug status in the EU provides for incentives, including 10 years' of market exclusivity for the drug, if approved.
Seeking Alpha • Sep 16

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

A committee of the European Medicines Agency (EMA) recommended the approval of Amryt's (NASDAQ:AMYT) Mycapssa (octreotide capsules) in the EU as a maintenance therapy of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The decision of the EMA's Committee for Medicinal Products for Human Use (CHMP) was backed by data from a phase 3 trial called MPOWERED. The European Commission (EC), which generally follows the opinion of the CHMP, will now decide on the drug's approval. The EC decision is expected within within 67 days, the company said in a Sept. 16 press release. "The CHMP recommendation for approval of Mycapssa is a very significant development for acromegaly sufferers in Europe and Mycapssa would be the first and only oral somatostatin analog approved in the EU," said Amryt CEO Joe Wiley.
Seeking Alpha • Sep 08

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Irish commercial-stage biopharma Amryt (NASDAQ:AMYT) on Thursday said UK's drug regulator had approved its Filsuvez gel to treat wounds associated with genetic skin disorder epidermolysis bullosa (EB). U.S.-listed shares of AMYT were 3.5% higher at $7.93 in premarket trading. The UK's Medical Healthcare & Products Regulatory Agency granted a marketing authorization and an orphan drug designation to Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months and older, AMYT said in a statement. "We look forward to continuing our discussions with the reimbursement agencies across the UK and European Union to begin delivering Filsuvez to treat patients as soon as possible...," AMYT CEO Joe Wiley said. The nod from the British regulator comes after the European Commission approved Filsuvez in Aug. The U.S. FDA rejected the company's approval application for Filsuvez in Feb., with Amryt (AMYT) later saying it would appeal the so-called complete response letter.
Seeking Alpha • Jul 14

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat carcinoid syndrome (CS). CS occurs when a rare cancerous tumor called carcinoid tumor releases certain chemicals in the blood, causing several symptoms. According to the company CS is the most common functional syndrome associated with neuroendocrine tumours (NETs). Mycapssa (oral octreotide) is approved by the FDA as a long-term maintenance therapy for certain patients with acromegaly, a hormonal disorder which occurs when the pituitary gland produces too much growth hormone during adulthood. Amryt noted that its TPE platform enables the oral delivery of the octreotide molecule which is otherwise delivered as an injectable. The FDA grants orphan drug status to therapies that treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including seven years of market exclusivity, if approved. AMYT +11.19% to $8.25 premarket July 14.
Seeking Alpha • Jun 23

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

The European Commission (EC) approved Amryt's (NASDAQ:AMYT) Filsuvez to treat partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare disease in which the skin becomes fragile and can tear or blister from minor injury/rubbing. Filsuvez will be the first and only approved therapy for patients EB, the Dublin-based company said in a June 23 press release. The approval was backed by data from a phase 3 trial called EASE which included 58 sites in 28 countries. The company noted that authorization of Filsuvez® in the EU provides a regulatory core dossier which may form the basis for future regulatory submissions in LATAM and the Middle East. A day ago, Krystal Biotech (KRYS) filed for U.S. approval of its topical gene therapy B-VEC to treat patients with dystrophic EB.

Recent updates

Seeking Alpha • Oct 18

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

A committee of the European Medicines Agency (EMA) recommended that the orphan disease designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat acromegaly in the EU is maintained. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The EMA's Committee for Orphan Medicinal Products (COMP) adopted the positive opinion. "The COMP recommendation to maintain the orphan disease designation for Mycapssa confirms the significant benefit of Mycapssa over the currently available injectable forms of somatostatin analogues, which represents a significant development for acromegaly sufferers in Europe," said Amryt CEO Joe Wiley. In September, EMA's Committee for Medicinal Products for Human Use (CHMP) had recommended the approval of Mycapssa as a maintenance therapy for certain patients with acromegaly. The orphan drug status in the EU provides for incentives, including 10 years' of market exclusivity for the drug, if approved.
Seeking Alpha • Sep 16

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

A committee of the European Medicines Agency (EMA) recommended the approval of Amryt's (NASDAQ:AMYT) Mycapssa (octreotide capsules) in the EU as a maintenance therapy of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The decision of the EMA's Committee for Medicinal Products for Human Use (CHMP) was backed by data from a phase 3 trial called MPOWERED. The European Commission (EC), which generally follows the opinion of the CHMP, will now decide on the drug's approval. The EC decision is expected within within 67 days, the company said in a Sept. 16 press release. "The CHMP recommendation for approval of Mycapssa is a very significant development for acromegaly sufferers in Europe and Mycapssa would be the first and only oral somatostatin analog approved in the EU," said Amryt CEO Joe Wiley.
Seeking Alpha • Sep 08

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Irish commercial-stage biopharma Amryt (NASDAQ:AMYT) on Thursday said UK's drug regulator had approved its Filsuvez gel to treat wounds associated with genetic skin disorder epidermolysis bullosa (EB). U.S.-listed shares of AMYT were 3.5% higher at $7.93 in premarket trading. The UK's Medical Healthcare & Products Regulatory Agency granted a marketing authorization and an orphan drug designation to Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months and older, AMYT said in a statement. "We look forward to continuing our discussions with the reimbursement agencies across the UK and European Union to begin delivering Filsuvez to treat patients as soon as possible...," AMYT CEO Joe Wiley said. The nod from the British regulator comes after the European Commission approved Filsuvez in Aug. The U.S. FDA rejected the company's approval application for Filsuvez in Feb., with Amryt (AMYT) later saying it would appeal the so-called complete response letter.
Seeking Alpha • Jul 14

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat carcinoid syndrome (CS). CS occurs when a rare cancerous tumor called carcinoid tumor releases certain chemicals in the blood, causing several symptoms. According to the company CS is the most common functional syndrome associated with neuroendocrine tumours (NETs). Mycapssa (oral octreotide) is approved by the FDA as a long-term maintenance therapy for certain patients with acromegaly, a hormonal disorder which occurs when the pituitary gland produces too much growth hormone during adulthood. Amryt noted that its TPE platform enables the oral delivery of the octreotide molecule which is otherwise delivered as an injectable. The FDA grants orphan drug status to therapies that treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including seven years of market exclusivity, if approved. AMYT +11.19% to $8.25 premarket July 14.
Seeking Alpha • Jun 23

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

The European Commission (EC) approved Amryt's (NASDAQ:AMYT) Filsuvez to treat partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare disease in which the skin becomes fragile and can tear or blister from minor injury/rubbing. Filsuvez will be the first and only approved therapy for patients EB, the Dublin-based company said in a June 23 press release. The approval was backed by data from a phase 3 trial called EASE which included 58 sites in 28 countries. The company noted that authorization of Filsuvez® in the EU provides a regulatory core dossier which may form the basis for future regulatory submissions in LATAM and the Middle East. A day ago, Krystal Biotech (KRYS) filed for U.S. approval of its topical gene therapy B-VEC to treat patients with dystrophic EB.
Seeking Alpha • Dec 09

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Amryt Pharma is developing and delivering innovative medicines for rare and debilitating conditions. The Company has acquired three companies since formation, and has commercialized three medicines. The Company also has a significant development pipeline.

Aktionärsrenditen

AMYTUS PharmaceuticalsUS Markt
7D0.7%5.4%1.2%
1Y86.5%44.3%28.7%

Rendite im Vergleich zur Industrie: AMYT übertraf die Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 44.3 erzielte.

Rendite vs. Markt: AMYT übertraf den Markt US, der im vergangenen Jahr eine Rendite von 28.7 erzielte.

Preisvolatilität

Is AMYT's price volatile compared to industry and market?
AMYT volatility
AMYT Average Weekly Movement0.4%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stabiler Aktienkurs: Der Aktienkurs von AMYT war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.

Volatilität im Zeitverlauf: AMYTDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 16% auf 0% zurückgegangen.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
2015289Joe Wileywww.amrytpharma.com

Amryt Pharma plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Amryt Pharma im Vergleich zum Marktanteil des Unternehmens?
AMYT grundlegende Statistiken
MarktanteilUS$940.67m
Gewinn(TTM)-US$790.00k
Umsatz(TTM)US$243.62m
3.9x
Kurs-Umsatz-Verhältnis
-1,191x
Kurs-Gewinn-Verhältnis

Ist AMYT zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
AMYT Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$243.62m
Kosten der EinnahmenUS$111.31m
BruttogewinnUS$132.32m
Sonstige AusgabenUS$133.11m
Gewinn-US$790.00k

Zuletzt gemeldete Gewinne

Sep 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-0.012
Bruttomarge54.31%
Nettogewinnspanne-0.32%
Schulden/Eigenkapital-Verhältnis64.3%

Wie hat sich AMYT auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2023/04/14 04:03
Aktienkurs zum Tagesende2023/04/11 00:00
Gewinne2022/09/30
Jährliche Einnahmen2021/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Amryt Pharma plc wird von 8 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Michelle GilsonCanaccord Genuity
Brandon FolkesCantor Fitzgerald & Co.
Andrew YoungDavy